This technology is designed to support early discovery efforts, hypothesis generation, and mechanistic studies in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other neurodegenerative disorders.
Each signature is distinguished by cell-type–specific patterns using a proprietary algorithm and reported as an estimate of relative cfDNA levels per sample.
Capture and quantify cfDNA derived from key neural and glial subtypes:
Cortical neurons
Dopaminergic neurons
Spinal Motor Neurons
Astrocytes
Microglia
Schwann cells
Assess cfDNA patterns in cognitively normal, at-risk, and neurodegenerative cohorts to uncover disease trends.
Use cfDNA signals to evaluate neurodegenerative pharmacodynamics and investigate new biomarkers.
Analyze CNS cell-type dynamics over time through minimally invasive, cfDNA-based profiling.
Identify candidate markers for stratification or progression based on cfDNA cell-of-origin signatures.
Optimized for cfDNA from human plasma
Captures brain cell signals from one draw
Quantifies cell-type–specific cfDNA signatures
Delivers univariate and bivariate plots for group analysis
Resonant partners with academic labs, biotech teams, and translational researchers. Let’s explore how Resonant’s cfDNA platform can support your neurodegeneration research.
